This metabolic rewiring provides a strong biological rationale for precision therapeutics.We trace the clinical development of desaturase inhibitors, highlighting the recent entry of SCD1 inhibitor, MTI-301, in a Phase 1 clinical trial for solid tumors and the potential repurposing of Aramchol, while detailing how FADS2 plasticity (the "sapienic shunt") drives therapeutic resistance. By integrating these insights into desaturation lipidomics, metabolic modulation via diet-drug interactions, synergistic combination regimens, and stimuli-responsive nanomedicine, we highlight the translational potential of targeting lipid desaturation to overcome metabolic plasticity and treatment resistance in aggressive malignancies.

P1, N=18, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P=N/A, N=1952, Recruiting, Yonsei University | Not yet recruiting --> Recruiting

P=N/A, N=5000, Not yet recruiting, Samsung Medical Center

P1, N=16, Completed, Galmed Pharmaceuticals Ltd | Active, not recruiting --> Completed

Pharmacologic and dietary modulators: Statin, ezetimibe, and ω-3 fatty acids can remodel cholesterol pools, reverse raft stabilization, and partially restore sensitivity to targeted or immune therapies in preclinical models. Recognizing cholesterol metabolism as a contributing factor to oncogenic signaling and immune suppression highlights potential theoretical avenues for biomarker-guided treatment combinations. This integrative framework positions cholesterol not only as a structural lipid but also as a dynamic regulator of tumor evolution and therapy response.

P4, N=1200, Active, not recruiting, Yonsei University | Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2025 --> Oct 2027

Moreover, mice fed a diet containing both cholesterol and alcohol exhibited increased expression of monocyte chemoattractant protein 1 (Mcp1) and tumor necrosis factor alpha (Tnfα) in the distal small intestine. Collectively, our findings indicate that ezetimibe effectively mitigates the adverse effects of dietary cholesterol and alcohol consumption on hepatic lipid accumulation and liver injury.

Sixty rats were used in the study, divided into the following groups: a control group (healthy rats), a diabetic control group, a diabetic group treated with metformin, a diabetic group treated with ezetimibe, a diabetic group treated with ezetimibe plus L-NAME, and a diabetic group treated with ezetimibe plus L-arginine. However, the beneficial effects of ezetimibe were reversed by L-NAME. Ezetimibe protected the kidney against diabetic injury mainly by activating the nitric oxide signaling pathway, enhancing antioxidant enzyme activity, and reducing inflammation, suggesting that its nephroprotective effects are NO-dependent.

P=N/A, N=60, Not yet recruiting, Melbourne Health

P=N/A, N=1952, Not yet recruiting, Yonsei University

P=N/A, N=10000, Recruiting, JW Pharmaceutical